Abstract: AIMS: High-density lipoprotein (HDL) cholesterol is a strong predictor of cardiovascular mortality. This work aimed to investigate whether the presence of coronary artery disease (CAD) impacts on its predictive value. METHODS AND RESULTS: We studied 3141 participants (2191 males, 950 females) of the LUdwigshafen RIsk and Cardiovascular health (LURIC) study. They had a mean ± standard deviation age of 62.6 ± 10.6 years, body mass index of 27.5 ± 4.1 kg/msup2;, and HDL cholesterol of 38.9 ± 10.8 mg/dL. The cohort consisted of 699 people without CAD, 1515 patients with stable CAD, and 927 patients with unstable CAD. The participants were prospectively followed for cardiovascular mortality over a median (inter-quartile range) period of 9.9 (8.7-10.7) years. A total of 590 participants died from cardiovascular diseases. High-density lipoprotein cholesterol by tertiles was inversely related to cardiovascular mortality in the entire cohort (P = 0.009). There was significant interaction between HDL cholesterol and CAD in predicting the outcome (P = 0.007). In stratified analyses, HDL cholesterol was strongly associated with cardiovascular mortality in people without CAD [3rd vs. 1st tertile: HR (95% CI) = 0.37 (0.18-0.74 
Introduction

1
Epidemiologic data have provided broad evidence that low concentrations of high-density 2 lipoprotein (HDL) cholesterol indicate increased cardiovascular risk (1) (2) (3) (4) . Although less 3 consistently (5), this relationship is even apparent in patients treated with statins (6) . 4 Therefore, raising HDL cholesterol has become a therapeutic target in coronary artery disease 5 (CAD) (7) . 6 Inhibition of cholesterol-ester transfer protein (CETP) is associated with a substantial increase 7 of HDL cholesterol (8) (9) (10) (11) (12) . Nevertheless, the use of torcetrapib did not improve but rather 8 worsened prognosis in the ILLUMINATE trial (11). Treatment with dalcetrapib did not 9 reduce the risk of cardiovascular events in the recently published dal-OUTCOMES trial either 10 (12). These disappointing results may in part be attributed to off-target effects of cholesterol 11 ester transfer protein (CETP) inhibitors, most importantly an increase in systolic blood 12 pressure and pro-inflammatory activity (11, 12 ). An alternative explanation would be that 13 raising HDL cholesterol is less beneficial in certain subgroups, for example in patients with 14 CAD. Notably, ILLUMINATE included patients at high cardiovascular risk and all 15 participants of the dal-OUTCOMES trial had suffered a recent acute coronary syndrome (11. 16 
12). 17
Therefore, the aim of the present study was to investigate, whether CAD at baseline affects 18 the prognostic value of HDL cholesterol for cardiovascular mortality. The exploratory 19 analyses were performed in the "LUdwigshafen RIsk and Cardiovascular health" (LURIC) 20 cohort (13, 14). Replication of the findings obtained from LURIC was sought in the 21
AtheroGene (15, 16) and the ESTHER (17, 18) cohorts. Considering that their clinical 22 presentation, treatment, and prognosis differ markedly, stable and unstable CAD were 23 analyzed separately. 24
Methods
Laboratory analyses 1
All analyses were performed in fasting blood samples. In the LURIC and AtheroGene 2 cohorts, the blood samples were collected before angiography (13-16). In the ESTHER 3 cohort, the blood samples were taken during the health check-up (17, 18) . 4 In the LURIC cohort, the lipoproteins were separated using a combined ultracentrifugation-5 precipitation method (ß quantification) (13). Cholesterol was measured with enzymatic 6 reagents from WAKO (Neuss, Germany) on a WAKO 30 R or Olympus AU640 (Tokyo, 7 Japan) analyzer (13). Triglycerides were quantified with an enzymatic colour assay on a 8
Hitachi 717 analyzer (Roche, Mannheim, Germany) (13). Apoplipoproteins A1, A2, and B 9
were measured by turbidimetry (Rolf-Greiner Biochemica, Flacht, Germany) (13). In the 10
AtheroGene cohort, total cholesterol, triglycerides were measured enzymatically (Roche 11 Diagnostics, Mannheim, Germany). HDL cholesterol was measured after masking 12 apolipoprotein B immunologically (Rolf Greiner Biochemica, Flacht, Germany). LDL 13 cholesterol was calculated by the Friedewald formula (15, 16) . In the ESTHER cohort, total 14 cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were measured with 15 standard methods (17, 18) . 16
Statistical analysis 18
Tertiles of HDL cholesterol were formed in each cohort. The baseline characteristics are 19 presented as counts and percentages of subjects in cases of categorical data and as means and 20 standard deviations or medians with inter-quartile ranges in cases of continuous data for the 21 tertiles of HDL cholesterol. The χ²-test and ANalysis Of VAriance were used to compare the 22 distributions of the variables across the tertiles of HDL cholesterol. Triglycerides Wilk W test) were transformed logarithmically before being used in parametric statistical 24 procedures. The Cox proportional hazards model was used to examine the association 25 between HDL cholesterol and time to cardiovascular death. For exploratory purposes, the 26 associations of the HDL cholesterol tertiles with cardiovascular mortality were first studied in 1 the entire LURIC cohort. Two predefined models of adjustment were used (model 1: adjusted 2 for sex, age, and CAD; model 2: adjusted for sex, age, body mass index, systolic and 3 diastolic blood pressure, diabetes mellitus, smoking, glomerular filtration rate, triglycerides, 4 low density lipoprotein cholesterol, medication use (insulin, oral antidiabetic, ß-Blocker, ACE 5 inhibitor, calcium antagonist, diuretic, acetyl salicylic acid, and statin), and CAD). Moreover, 6
the interaction between the HDL cholesterol tertiles and CAD with regard to cardiovascular 7 mortality was studied by including the interaction term as a covariate. In the next step, 8 stratified analyses in people without CAD, in patients with stable CAD, and in patients with 9 unstable CAD were conducted using the aforementioned models of adjustment. For 10 replication, the associations of the HDL cholesterol tertiles with cardiovascular mortality were 11 studied in the AtheroGene and ESTHER cohorts, which were stratified accordingly. All 12 statistical tests were 2-sided and p values <0.05 were considered significant. The SPSS 19.0 13 statistical package (SPSS Inc., Chicago, USA) was used in the LURIC and ESTHER cohorts. 14 The R statistical software package (http://www.r-project.org) was used in the AtheroGene 15 cohort. For meta-analyses of the results obtained from the LURIC, AtheroGene, and ESTHER 16 cohorts, HRs were pooled by the inverse of the variance method in a fixed effects model with 17 the software Comprehensive Meta-Analysis®. 18 
19
Role of the funding source 20
The funding source was not involved in study design, in the collection, analysis, and 21 interpretation of data, in the writing of the report, and in the decision to submit the paper for 22 publication. 23
Results
1
LURIC 2
Baseline characteristics 3
The study participants (2, 191 males, 950 females) had a mean ± standard deviation age of 4 62.6 ± 10.6 years, body mass index of 27.5 ± 4.1 kg/m², and HDL cholesterol of 38.9 ± 10.8 5 mg/dl. High HDL cholesterol was associated with female gender, lower body mass index and 6 waist circumference, and lower proportion of subjects with diabetes mellitus ( according to the presence of CAD. In stratified analyses, the association between the HDL 8 cholesterol tertiles and cardiovascular mortality was strong in people without CAD whereas it 9 was weak and non-significant after multivariate adjustment in patients with stable and 10 unstable CAD. Very similar observations were made in the AtheroGene cohort. The 11 aforementioned differences were less pronounced in the ESTHER cohort, possibly due to the 12 lack of coronary angiograms and consequently a large proportion of undiagnosed, silent CAD. 13
Finally, a meta-analysis comprising all three cohorts was performed and the results were in 14 support of the LURIC findings. 15
Previous studies have not specifically addressed an interaction of HDL with CAD, probably 16 because very few studies have collected precise information on both, CAD at baseline and 17 cardiovascular death. However, our results are in agreement with evidence from the dal-18 OUTCOMES trial (12). In this cohort of 15,871 patients, who had suffered acute coronary 19 syndromes, HDL cholesterol was not predictive of the primary end-point (12). Moreover, the 20 present observations are confirmed by recent data on the cholesterol efflux capacity from 21 macrophages to serum, which is positively related to HDL cholesterol (19, 20) . In cross-22 sectional analyses, low cholesterol efflux capacity was repeatedly associated with higher 23 prevalence of CAD (19, 20) . At the same time, the cholesterol efflux capacity was positively 24 associated with the risk of future vascular complications in patients with CAD whereas no 25 such paradox association was seen in an outpatient cohort (20) . 26 Two potential reasons, that may explain the interaction between the HDL cholesterol tertiles 1 and CAD with regard to cardiovascular mortality, shall be highlighted: First, dysfunctional 2 HDL may account for weaker associations of HDL cholesterol with cardiovascular mortality 3 in CAD. HDL is considered to represent the major vehicle of reverse cholesterol transport 4 (21) (22) (23) . In addition, HDL may exert anti-inflammatory effects, prevent low-density 5 lipoprotein oxidation, and play an important role in nitric oxide synthesis (21) (22) (23) . Even anti-6 thrombotic potency has been suggested (21) (22) (23) . Nevertheless, there is growing knowledge 7 that the vascular protective properties of HDL are impaired in certain diseases (24, 25) . Most 8 importantly, the anti-inflammatory and anti-oxidative effects of HDL were demonstrated to be 9 reduced in CAD (26, 27) . In the LURIC cohort, the apolipoprotein A1 and A2 composition of 10 14. O Hartaigh B, Bosch JA, Carroll D, Hemming K, Pilz S, Loerbroks A, Kleber ME, Grammer TB, Fischer JE, Boehm BO, März W, Thomas GN. Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. Eur Heart J 2013;34:932-941. Legend: N number; CD number of cardiovascular deaths (percentage of tertile); HR hazard ratio; * adjusted for sex and age; † adjusted for sex, age, body mass index, systolic and diastolic blood pressure (hypertension in the AtheroGene cohort), diabetes, smoking, glomerular filtration rate, Legend: HR hazard ratio; * adjusted for sex and age; † adjusted for sex, age, body mass index, systolic and diastolic blood pressure, diabetes, smoking, glomerular filtration rate, triglycerides, LDL cholesterol, and medication use (insulin, oral antidiabetic, ß-Blocker, ACE inhibitor, calcium antagonist, diuretic, acetyl salicylic acid, and statin); for participants without CAD including data from LURIC and AtheroGene cohorts only
Supplementary text
1 LURIC 2
Clinical characterisation 3
Information on socio-demographic characteristics, lifestyle and a history of common diseases 4 were obtained by a comprehensive questionnaire from the study participants and from 5 medical records at baseline (1). 6
Diabetes mellitus was newly diagnosed according to the 2010 criteria of the American 7 Diabetes Association. Thus, participants were categorised as diabetic if fasting plasma 8 glucose was ≥126 mg/dl and/or plasma post-challenge glucose (plasma glucose 2 hours after 9 the 75g glucose load) was ≥200 mg/dl and/or glycated hemoglobin was ≥6.5% (2) . Moreover 10 patients with a history of diabetes and those using oral anti-diabetics or insulin were 11 considered diabetic. 
Clinical characterisation 21
Information on socio-demographic characteristics, lifestyle and a history of common diseases 22
were obtained by a comprehensive questionnaire from the study participants and from 23 medical records at baseline (4) . 24 Diabetes mellitus was diagnosed if fasting plasma glucose was ≥126 mg/dl. Moreover, 1 patients with a history of diabetes and those using oral anti-diabetics or insulin were 2 considered diabetic (4). 
Clinical characterisation 12
Information on socio-demographic characteristics, lifestyle and a history of common diseases 13 were obtained by a comprehensive questionnaire from the study participants at baseline. 14 Diabetes mellitus was diagnosed based on reports of physicians. In addition, diabetes was 15 identified by use of anti-diabetic medication and/or fasting plasma glucose ≥126 mg/dl and/or 16 non-fasting glucose ≥200 mg/dl and/or glycated hemoglobin ≥6.5% (7) . 17
Hypertension was diagnosed based on reports of physicians. In addition, hypertension was 18 identified by use of antihypertensive drugs and/or self-reported hypertension plus a systolic 19 blood pressure ≥140 and/or a diastolic blood pressure ≥90 mmHg. 20
Cerebrovascular disease was self-reported by study participants in the standardized 21 questionnaire in a question on any kind of stroke in the past. 22
Peripheral vascular disease was defined by a self-reported history of a balloon dilatation of 23 the of leg arteries. 24 
5
Laboratory examination 1 Serum creatinine was determined by kinetic Jaffé method (8) . Estimated glomerular filtration 2 rate was calculated according to the Modification of Diet in Renal Disease equation (9) 
